Freddy Yip

Cooley advised Jiangsu Hengrui Pharmaceuticals, a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing and commercialization of innovative and high-quality healthcare products, on its strategic collaboration and exclusive worldwide (excluding mainland China) license agreement with Merck KGaA, Darmstadt, Germany and global license agreement (excluding the Greater China region and Korea) with Elevar Therapeutics.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.

Cooley advised Cholesgen, a biopharmaceutical company focusing on metabolic diseases, on its three-year research collaboration and licensing agreement with AstraZeneca.

Cooley advised Zai Lab, a research-based commercial-stage biopharmaceutical company, on its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as part of Zai Lab’s efforts to build its portfolio of potential first- and/or best-in-class antibody-drug conjugate (ADC) products.